Why IBD Stock Of The Day Harrow Has Its Sights On A Breakout

			Harrow			

				Harrow				

			HROW			

$ 52.25

			$0.70
			
			
			![](https://img-cdn.gateio.im/social/moments-a1b506ebdb-88035ca254-8b7abd-d8d215)
			1.36%
			
			
			![](https://img-cdn.gateio.im/social/moments-78d80cff6f-40f3678069-8b7abd-d8d215)
			24%

IBD Stock Analysis

										*   Stock eyeing handle on a seven-week cup
										*   HROW finds support at 10-week
								

		

		

			![](https://img-cdn.gateio.im/social/moments-92a340c1ae-579ada3380-8b7abd-d8d215)

Composite Rating

					![](https://img-cdn.gateio.im/social/moments-929093bd5d-b9758c1877-8b7abd-d8d215)

96/99

Industry Group Ranking

		![](https://img-cdn.gateio.im/social/moments-cf0c8767dd-dd23927ed2-8b7abd-d8d215)

26/197

Emerging Pattern

			![](https://img-cdn.gateio.im/social/moments-c10446ff6c-f3f3a8618e-8b7abd-d8d215)
			

				Cup

Cup

				A cup-shaped pattern with no handle. Must be at least six weeks long or as long as a year. Buy point is 10 cents above the left-side high.				

• Not real-time data. All data shown was captured at 11:54AM EST on 02/23/2026.

Harrow (HROW) is Monday’s IBD Stock Of The Day. The biotech stock is setting up to tack a possible handle onto a seven-week cup as enthusiasm grows for its eye-disease treatments.

Investors are keenly focused on demand for Vevye, a preservative- and water-free eye drop used twice a day to treat dry eye disease.

				    ↑
					X
					
						
					      

							

								These Three Catalysts Could Make Medical Stocks A Healthy Bet In 2026
							

							

								See All Videos
							

						

					
					
						NOW PLAYING
						These Three Catalysts Could Make Medical Stocks A Healthy Bet In 2026

But other things are becoming clearer for Harrow.

On Feb. 11, Samsung Bioepis announced it reached an agreement with Regeneron Pharmaceuticals (REGN) to launch an Eylea biosimilar, Opuviz, in the U.S. in January 2027. That’s earlier than previous expectations for mid-2027. Harrow is Samsung Bioepis’ commercial partner for biosimilar products — knockoffs of biologic drugs like Eylea.

Eylea treats a handful of eye diseases. It notched massive U.S. sales that peaked north of $6 billion in 2022. Eylea sales are dropping quickly, however, as biosimilars begin to take a chunk. William Blair analyst Lachlan Hanbury-Brown notes that Harrow/Samsung Bioepis will face a fair number of biosimilar competitors for their lower-cost version of Eylea.

“While we are cautiously optimistic that Harrow’s broad portfolio in retina will allow it to differentiate from competitors, we are keeping our estimates conservative for now as we wait to see how the market evolves over the coming year,” he said in a report.

Biotech Stock Sets Sights On A Breakout

Still, Harrow shares continue to shine. The biotech stock has gained more than 6% this year, as of Friday’s close, after ramping up 46% in 2025. Shares have support at their 10-week moving average as they possibly work on adding a handle to a seven-week cup base, according to MarketSurge. The cup base currently has a buy point of 54.85.

The Opuviz opportunity is larger than the opportunity for Byooviz, another Samsung Bioepis-partnered biosimilar. Byooviz is a copycat of Novartis’ (NVS) Lucentis, a treatment for wet age-related macular degeneration, or wet AMD. Harrow acquired the rights to sell Byooviz in the U.S. from Biogen (BIIB), with plans to close the deal at the end of 2025.

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

		SIGN UP NOW!

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

										*   							
								How To Invest								
								
							
						
										*   							
								Market Prep								
								
							
						
										*   							
								Tech Report								

Please enter a valid email address

Please select a newsletter

			GO

Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use

		x

Thank You!

You will now receive IBD Newsletters

			ALL DONE!

Something Went Wrong!

Please contact customer service

			CLOSE

Beyond its biosimilars, investors are keeping a close eye on Vevye. The company plans to double its covered U.S. territories for the dry eye drug by Memorial Day. The effort comes after the largest U.S. commercial pharmacy benefit manager agreed to reimburse patients for the cost of Vevye.

Harrow is also doubling the size of its surgical salesforce for Triesence. Triesence treats severe eye inflammation, but it can also be used during eye surgery.

“The company has also seen a sustained increase in interest in Triesence adoption and reordering as an injectable anti-inflammatory in both office and surgical settings,” Hanbury-Brown said in a separate report.

Further, Harrow is expanding its commercial focus for Iheezo beyond retina practices to office-based settings. Iheezo is a gel that helps numb the eye before surgery. The company says there are about 2.5 million annual office-based ophthalmic procedures for which Iheezo could be used.

Strong Expectations For 2025 Sales

Earlier this month, Harrow reaffirmed its expectation for $270 million to $280 million in full-year sales for 2025. At the midpoint, sales would grow almost 38% vs. 2024. The biotech company is due to report its fourth-quarter earnings on March 2. Hanbury-Brown, the William Blair analyst, hiked his view for 2025 sales to $270.7 million, driven by increased adoption for Iheezo and other branded drugs.

He rates the biotech stock an outperform.

Broadly, analysts call for $273.8 million in last-year sales from Harrow, according to FactSet. All eight of the analysts who cover the biotech stock rate it a buy or equivalent.

Notably, Harrow also recently confirmed its plans in the first half of next year to seek Food and Drug Administration approval of a drug it calls MELT-300.

MELT-300 is a dissolvable tablet that includes equal parts midazolam and ketamine to sedate patients before surgery.

Harrow accessed MELT-300 through its takeover of Melt Pharmaceuticals, which closed in November. It builds on Harrow’s MKO Melt, a similar product sold by Harrow’s subsidiary, ImprimisRx.

Highly Rated Biotech Stock

Harrow stock has a strong IBD Digital Composite Rating of 96 and a Relative Strength Rating of 93. This means the biotech stock ranks in the leading 4% of all stocks when it comes to fundamental and technical performance, and in the top 7% in terms of 12-month performance.

The EPS Rating is a somewhat lower 79, reflecting recent profitability trends.

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J

Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly’s Kingpin

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Options Trading: How To Start Using Options, How To Manage Risk

Join IBD Live For Stock Ideas Each Morning Before The Open